Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up.
about
PLK1, A Potential Target for Cancer TherapyThe clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: a systematic review and meta-analysis.LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.Calein C, a Sesquiterpene Lactone Isolated From (), Inhibits Mitotic Progression and Induces Apoptosis in MCF-7 Cells
P2860
Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Augmented expression of Polo-l ...... t cancer at 15-year follow-up.
@en
type
label
Augmented expression of Polo-l ...... t cancer at 15-year follow-up.
@en
prefLabel
Augmented expression of Polo-l ...... t cancer at 15-year follow-up.
@en
P2093
P2860
P50
P356
P1433
P1476
Augmented expression of Polo-l ...... st cancer at 15-year follow-up
@en
P2093
Agnieszka Halon
Piotr Donizy
Rafal Matkowski
P2860
P304
P356
10.3892/OL.2016.4890
P577
2016-07-20T00:00:00Z